Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes - ScienceDirect
Vaccines | Free Full-Text | Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial - American Journal of Transplantation
Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes - ScienceDirect
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm | Nature Communications
Tocilizumab in patients with severe COVID-19: a retrospective cohort study - The Lancet Rheumatology
Antibiotics | Free Full-Text | Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study
Antibiotics | Free Full-Text | Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France
Anti-hIL-6R mAbs | Tocilizumab | InvivoGen
![Anti-Tocilizumab Antibody (6C10)[Biotin], mAb, Mouse - GenScript](https://www.genscript.com/product/documents/down?doc_name=A01980_ELISA.jpg&file=scm_files/productFile_notes/2018/07/10/962f63cfb89db153989316cd79f2628a.jpg "Anti-Tocilizumab Antibody (6C10)[Biotin], mAb, Mouse - GenScript")
Anti-Tocilizumab Antibody (6C10)[Biotin], mAb, Mouse - GenScript
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
Tocilizumab in COVID-19 management: addressing time of starting treatment | European Journal of Hospital Pharmacy
Pharmaceutics | Free Full-Text | Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
Blockage of interleukin-1β with canakinumab in patients with Covid-19 | Scientific Reports
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia | NEJM
RoActemra, INN-tocilizumab
Frontiers | Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review
Interleukin 6 Inhibition and Coronary Artery Disease in a High‐Risk Population: A Prospective Community‐Based Clinical Study | Journal of the American Heart Association
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes - ScienceDirect
Co-amorphous Systems of Sinomenine with Platensimycin or Sulfasalazine: Physical Stability and Excipient-Adjusted Release Behavior | Molecular Pharmaceutics
RoActemra, INN-tocilizumab
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA) | Annals of the Rheumatic Diseases
